Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
© 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within t...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/44884 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-44884 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-448842018-04-25T07:57:21Z Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use Yohei Sotomi Pannipa Suwannasom Erhan Tenekecioglu Hiroki Tateishi Mohammad Abdelghani Patrick W. Serruys Yoshinobu Onuma Agricultural and Biological Sciences © 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, neoatherosclerosis, permanent impairment of the physiological vasomotor function and interference with potential future grafting of the stented segment. Bioresorbable scaffolds have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress and mechanotransduction. This article presents a comparison between the most widespread bioresorbable vascular scaffold 'Absorb BVS' and second-generation drug-eluting stent (cobalt chromium everolimus-eluting stent) from bench to clinical use. 2018-01-24T04:49:29Z 2018-01-24T04:49:29Z 2015-01-01 Journal 17448344 14779072 2-s2.0-84942627294 10.1586/14779072.2015.1089172 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/44884 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
topic |
Agricultural and Biological Sciences |
spellingShingle |
Agricultural and Biological Sciences Yohei Sotomi Pannipa Suwannasom Erhan Tenekecioglu Hiroki Tateishi Mohammad Abdelghani Patrick W. Serruys Yoshinobu Onuma Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use |
description |
© 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, neoatherosclerosis, permanent impairment of the physiological vasomotor function and interference with potential future grafting of the stented segment. Bioresorbable scaffolds have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress and mechanotransduction. This article presents a comparison between the most widespread bioresorbable vascular scaffold 'Absorb BVS' and second-generation drug-eluting stent (cobalt chromium everolimus-eluting stent) from bench to clinical use. |
format |
Journal |
author |
Yohei Sotomi Pannipa Suwannasom Erhan Tenekecioglu Hiroki Tateishi Mohammad Abdelghani Patrick W. Serruys Yoshinobu Onuma |
author_facet |
Yohei Sotomi Pannipa Suwannasom Erhan Tenekecioglu Hiroki Tateishi Mohammad Abdelghani Patrick W. Serruys Yoshinobu Onuma |
author_sort |
Yohei Sotomi |
title |
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use |
title_short |
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use |
title_full |
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use |
title_fullStr |
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use |
title_full_unstemmed |
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use |
title_sort |
differential aspects between cobalt-chromium everolimus drug-eluting stent and absorb everolimus bioresorbable vascular scaffold: from bench to clinical use |
publishDate |
2018 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/44884 |
_version_ |
1681422642337284096 |